HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

What can ongoing clinical trials of anticoagulants demonstrate?

Abstract
As the population ages, the burden of thromboembolic disease increases. The development of new anticoagulants that overcome the shortcomings of the vitamin K antagonists represents an important advance.Clinical evaluation of new anticoagulants typically begins in short-term indications, such as prophylaxis against venous thromboembolism in patients undergoing orthopaedic surgery, followed by investigation in chronic conditions, such as stroke prevention in patients with atrial fibrillation. Factors for consideration in clinical trials include methodological issues (blinded versus open-label; active-control statistical designs; patient selection, etc.). Despite its subsequent withdrawal, clinical trials of ximelagatran demonstrated the efficacy of fixed doses of an oral, direct thrombin inhibitor for prevention of thromboembolism. Direct and indirect inhibition of activated Factor X is another target for new anticoagulants. Evidence-based data from trials such as these will pave the way for new anticoagulants, with the goal of bringing optimum prophylactic therapy to those requiring anticoagulation.
AuthorsJonathan L Halperin
JournalJournal of cardiovascular medicine (Hagerstown, Md.) (J Cardiovasc Med (Hagerstown)) Vol. 10 Issue 8 Pg. 610-5 (Aug 2009) ISSN: 1558-2027 [Print] United States
PMID19553827 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Anticoagulants
  • Azetidines
  • Benzimidazoles
  • Benzylamines
  • Drugs, Investigational
  • Oligosaccharides
  • Pyridines
  • ximelagatran
  • idraparinux
  • Dabigatran
Topics
  • Anticoagulants (therapeutic use)
  • Azetidines (therapeutic use)
  • Benzimidazoles (therapeutic use)
  • Benzylamines (therapeutic use)
  • Clinical Trials as Topic (legislation & jurisprudence)
  • Dabigatran
  • Drugs, Investigational (therapeutic use)
  • Humans
  • Oligosaccharides (therapeutic use)
  • Pyridines (therapeutic use)
  • Thromboembolism (prevention & control)
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: